The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
Abstract
Endocrine therapies, first used more than 100 years ago, are the most effective treatments for breast cancers expressing the estrogen receptor (ER). All endocrine therapies are designed to block ER function in some way, thereby making them the first targeted therapies used for cancer. Selective ER modulators (SERMs) such as tamoxifen bindERandpartially block its activity.Ovarian ablation, luteinizing hormone–releasing hormone agonists, and aromatase inhibitors reduce the level of estrogen and inhibit ligand-induced activation of ER. Steroidal antiestrogens such as fulvestrant bind ER, more completely block its function, and induce receptor degradation.While all of these therapies are effective in certain patients, de novo and acquired resistance remain major problems. New information on the biology of ER provides insight into the mechanisms of treatment resistance and new strategies to overcome it, thereby potentially making these therapies even more effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Gene regulation by steroid hormones
Beato, M. (1989) · Cell · doi:10.1016/0092-8674(89)90237-7 · Cited by 3,383
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Self-citationMolecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Nuclear receptor coactivators and corepressors
Horwitz, K. B. (1996) · Molecular Endocrinology · doi:10.1210/me.10.10.1167 · Cited by 942
Estrogen receptor pathways to AP-1
Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., & Webb, P. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 870
Cited by
Computational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Virtual and biomolecular screening converge on a selective agonist for GPR30
Bologa, C. G., Revankar, C. M., Young, S. M., Edwards, B. S., Arterburn, J. B., Kiselyov, A. S., Parker, M. A., Tkachenko, S. E., Savchuck, N. P., Sklar, L. A., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio775 · Cited by 818
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Self-citationRole of Estrogens in the Regulation of Liver Lipid Metabolism
Palmisano, B. T., Zhu, L., & Stafford, J. M. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-70178-3_12 · Cited by 527
Sex differences in lipid and lipoprotein metabolism
Palmisano, B. T., Zhu, L., Eckel, R. H., & Stafford, J. M. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.008 · Cited by 522
Laganière, J., Deblois, G., Lefebvre, C., Bataille, A. R., Robert, F., & Giguère, V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505575102 · Cited by 367
Fu, Y., Li, J., & Lee, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4594 · Cited by 304
Metabolic Actions of Estrogen Receptor Beta (ERβ) are Mediated by a Negative Cross-Talk with PPARγ
Foryst-Ludwig, A., Clemenz, M., Hohmann, S., Hartge, M., Sprang, C., Frost, N., Krikov, M., Bhanot, S., Barros, R., Morani, A., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000108 · Cited by 287
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M., & Sherman, M. E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju165 · Cited by 265
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Self-citationGarcía-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
Regulatory Actions of Estrogen Receptor Signaling in the Cardiovascular System
Ueda, K., Adachi, Y., Liu, P., Fukuma, N., & Takimoto, E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00909 · Cited by 60
Recent insights into non-nuclear actions of estrogen receptor alpha
Banerjee, S., Chambliss, K. L., Mineo, C., & Shaul, P. W. (2014) · Steroids · doi:10.1016/j.steroids.2013.11.002 · Cited by 58
Sacharidou, A., Chambliss, K., Peng, J., Barrera, J., Tanigaki, K., Luby-Phelps, K., Özdemir, İ., Khan, S., Sirsi, S. R., Kim, S. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40562-w · Cited by 25
Liver biochemical abnormalities in adolescent patients with Turner syndrome
Wójcik, M., Ruszała, A., Januś, D., & Starzyk, J. B. (2019) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2019.2018.0271 · Cited by 13
“Both have the classic features of steroid hormone receptors (39).”
BackgroundBakadlag, R., Limniatis, G., Georges, G., & Georges, E. (2023) · BMC Cancer · doi:10.1186/s12885-022-10474-x · Cited by 9
“Its anti-proliferative effect as transcription inhibitor of estrogen-responsive genes is well established [43].”
Background
Metadata
- Authors
- Osborne, C. K., & Schiff, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-03-10
- Volume
- 23
- Issue
- 8
- Pages
- 1616-1622
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135278339
- Cited by
- 351
- References
- 56
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.